Remission Medical, a virtual rheumatology startup addressing a range of rheumatological conditions, including rheumatoid arthritis, osteoporosis, osteoarthritis, lupus, and gout, among others, raised a Series A funding round led by Blue Heron Capital.
The funding amount was not disclosed.
Blue Heron Capital is an early-stage growth equity firm funding big ideas in healthcare and enterprise technology. “What makes Remission Medical distinctive is the combination of a proven health system partnership model and a purpose-built technology platform that makes that model defensible at scale,” said Tom Benedetti, Partner at Blue Heron Capital.
According to the official press announcement, Remission Medical will use the fresh investment to fuel the growth of its partner network, clinical workforce, and scale up its infrastructure to rapidly deploy its rheumatology platform across more specialty systems beyond rheumatology.
The Series A round follows a period of significant commercial traction, including triple-digit growth over multiple years and expansion into new geographies across the company’s health system partner network.
Built from the ground up for value-based care and value-based benefits, Remission Medical partners with health systems, orthopedic practices, and other provider organizations with the goal of increasing access to much-needed rheumatology care for all patients.
Digital health companies have secured more than $180 billion in funding to date, driven by AI-powered healthcare workflow automation startups, according to our recent Funding Database. More recently, Luminai, a provider of an AI-powered healthcare workflow automation platform, raised $38 million in a Series B funding round, bringing its total funding to date to $60 million. San Francisco-based startup Luminai, formerly DigitalBrain, secured $16 million in a Series A funding round, following its $3.4 million seed round in October 2020.